

LISTING OF CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (**currently amended**): A method of specifically activating cytotoxic T lymphocytes ~~in vivo~~ in an animal having ~~malignant cells~~ a neoplasm that overexpresses a Her-2/Neu protein, the method comprising the step of ~~immunizing~~ administering the polypeptide of SEQ ID NO:12 to said animal having said neoplasm that overexpresses said Her-2/Neu protein with the polypeptide of SEQ ID NO:12.

Claims 2-60 (canceled)

Claim 61 (**currently amended**): A method of treating a patient having a ~~tumor~~ neoplasm and in need of treatment of said ~~tumor~~ neoplasm, wherein cells of said ~~tumor~~ neoplasm overexpress a Her-2/Neu protein, the method comprising the step of administering a polypeptide ~~having with~~ the amino acid sequence VMAGVGSPYV (SEQ ID NO:12) to the patient having said neoplasm wherein cells of said neoplasm overexpress said Her-2/Neu protein.

Claim 62 (previously presented): The method of claim 61, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- Claim 63 (previously presented): The method of claim 61, wherein said polypeptide is linked to a carrier.
- Claim 64 (previously presented): The method of claim 61, wherein said polypeptide is administered to said patient as a homopolymer.
- Claim 65 (previously presented): The method of claim 61, further comprising the step of administering a second component to said patient, wherein said second component primes cytotoxic T lymphocytes (CTLs) for activation.
- Claim 66 (**currently amended**): The method of claim 65, wherein the second component ~~comprises~~ is tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 67 (previously presented): The method of claim 61, further comprising the step of administering a second polypeptide to said animal.
- Claim 68 (**currently amended**): The method of claim 67, wherein the second polypeptide ~~comprises~~ is TPPAYRPPNAPIL (SEQ ID NO:9).
- Claim 69 (previously presented): The method of claim 1, wherein said polypeptide is incorporated into a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

- Claim 70 (previously presented): The method of claim 1, wherein said polypeptide is linked to a carrier.
- Claim 71 (previously presented): The method of claim 1, wherein said polypeptide is administered to said animal as a homopolymer.
- Claim 72 (previously presented): The method of claim 1, wherein said immunizing step further comprises administering a second component to said animal, wherein said second component primes said CTLs for activation.
- Claim 73 (**currently amended**): The method of claim 72, wherein said second component ~~comprises~~ is tripalmitoyl-S-glycerylcysteinyl-seryl-serine (P3CSS).
- Claim 74 (previously presented): The method of claim 1, wherein the immunizing step further comprises administering a second polypeptide to said animal.
- Claim 75 (**currently amended**): The method of claim 74, wherein the second polypeptide ~~comprises~~ is TPPAYRPPNAPIL (SEQ ID NO:9).